Long CGG-repeat tracts are toxic to human cells: Implications for carriers of Fragile X premutation alleles  by Handa, Vaishali et al.
FEBS Letters 579 (2005) 2702–2708 FEBS 29532Long CGG-repeat tracts are toxic to human cells: Implications for
carriers of Fragile X premutation alleles
Vaishali Handaa, Deena Goldwatera, David Stilesb, Margaret Camb, George Poyb,
Daman Kumaria, Karen Usdina,*
a Laboratory of Molecular and Cellular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health,
8 Center Drive MSC 0830, Bethesda, MD 20892-0830, United States
b Microarray Core Facility, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
MD 20892-0830, United States
Received 24 February 2005; revised 1 April 2005; accepted 5 April 2005
Available online 18 April 2005
Edited by Lev KisselevAbstract People with 59–200 CGG Æ CCG-repeats in the 5 0
UTR of one of their FMR1 genes are at risk for Fragile X tre-
mor and ataxia syndrome. Females are also at risk for prema-
ture ovarian failure. These symptoms are thought to be due to
the presence of the repeats at the DNA and/or RNA level. We
show here that long transcribed but untranslated CGG-repeat
tracts are toxic to human cells and alter the expression of a wide
variety of diﬀerent genes including caspase-8, CYFIP, Neuroten-
sin and UBE3A.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fragile X mental retardation syndrome (FXS) results from
the expansion of a tandem array of the triplet CGG Æ CCG
in the 5 0 UTR of the FMR1 gene [1,2]. Expansion occurs from
a maternal ‘‘premutation’’ allele containing 59–200
CGG Æ CCG-repeats and results in a ‘‘full mutation’’ allele
with >200 repeats [3]. In addition to the risk of having a child
with FXS, female ‘‘premutation’’ carriers also are at risk of
premature ovarian failure (Fragile X associated POF
(FXPOF) [4–8]), and all carriers are at risk for Fragile X tre-
mor and ataxia syndrome (FXTAS) [9]. The brains of aﬀected
individuals contain ubiquitin-positive nuclear inclusions [10],
that resemble those seen in disorders like Huntington disease
(HD) and Spinocerebellar ataxia type 7 (SCA7) that result
from expansion of a polyglutamine tract. This suggests paral-
lels between the mechanisms of disease pathology. However,
the signiﬁcance of these inclusions is unclear: in FXTAS Pur-
kinje cell drop out occurs in the absence of inclusions [10],
while in a mouse model, inclusions are plentiful in the absence
of neurodegeneration [11]; and in a mouse model of SCA7
there is an inverse correlation between neuropathology and
the number of inclusions [12].*Corresponding author. Fax: +1 301 402 0053.
E-mail address: ku@helix.nih.gov (K. Usdin).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
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known. FMRP levels in many premutation carriers are close
to normal and signiﬁcantly higher than carriers of full muta-
tion alleles who do not show these symptoms [13]. It thus
seems unlikely that the symptoms result from FMRP insuﬃ-
ciency. Premutation carriers not only have a longer than nor-
mal CGG-tract, but frequently also have higher than normal
levels of this RNA [14]. It has been suggested that this RNA
is somehow involved in ‘‘premutation’’ disease pathology
[15,16]. Long CGG-repeat tracts in RNA causes retinal degen-
eration when overexpressed in Drosophila [17], but very little is
known about the eﬀect of CGG-RNA in human cells or the
mechanism of repeat toxicity. We show here that expression
of long CGG-RNA aﬀects gene expression and cell survival.2. Materials and methods
2.1. Cell lines
The plasmids, pFRT0, pFRT22 and pFRT176 containing 0, 22 and
176 pure transcribed but untranslated CGG Æ CCG-repeats, have
been described previously [18]. pFRT30 and pFRT120 were con-
structed by cloning of PCR fragments containing the sequences
(CGG)9AGG(CGG)12AGG(CGG)7 and (CGG)9AGG(CGG)12-
AGG(CGG)97, respectively [19], into the SﬁI sites of pFRT0. The plas-
mids were used to generate the cell lines FRT0, FRT22, FRT30,
FRT120 and FRT176 by targeted insertion into a HEK293-derived
host cell line, Flp-In-293 (Invitrogen), according to the suppliers
instructions. The repeats in the FRT22 and FRT30 cell lines were se-
quenced. The repeat number in FRT120 was shown to be 120 by
PCR. Southern blotting showed that the repeat number in FRT176
ranged from 120 to 190. A number of other clones produced from
pFRT176 were also shown to have similar repeat heterogeneity. This
variation in repeat number is consistent with the known instability
of long triplet repeat tracts. It thus probably reﬂects the mechanism
that makes alleles of this length prone to expansion in humans, rather
than any second site mutation in FRT176 cells. All cell lines were
tested for mycoplasma infection using a Mycoplasma detection kit
(ATCC, Manassas, VA, USA) and conﬁrmed by direct culture and
Hoechst DNA staining.2.2. Cell culture conditions
The FRT cell lines were grown in Dulbeccos modiﬁed Eagles med-
ium (DMEM) containing 10% fetal bovine serum (tetracycline free),
100 lg/ml Normocin, 15 lg/ml Blasticidin S, 75 lg/ml Hygromycin in
a 37 C humidiﬁed incubator in a 5% CO2 atmosphere. Doxycycline
(2 lg/ml), staurosporine, paraquat and MG-132 were added where
indicated.blished by Elsevier B.V. All rights reserved.
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Survival was ascertained by trypan blue exclusion. Annexin V-posi-
tive cells were determined using the BD ApoAlert Annexin V detec-
tion kit (BD Biosciences, San Jose, CA, USA). Each cell line was tested
at least 3 times counting 700–1000 cells in each experiment. Caspase
activity was examined in 2 ways. Cell extracts were tested by Western
blotting using antibodies to caspase-1, -3, -8 and poly(ADP-ribose)
polymerase-1 (Upstate, Charlottesville, VA). Caspase-3 activity was
also monitored using a CleavaLite Caspase-3 Activity Assay Kit
according to the manufacturers instructions (Chemicon, Temecula,
CA, USA).
2.4. Gene expression analysis
RNA was isolated from three sets of dox-treated FRT176 and FRT0
cell lines and its quality checked using an Agilent Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). Microarray analysis was carried
out using Human U133A GeneChips (Aﬀymetrix, Santa Clara, CA,
USA). The resulting cel ﬁles were analyzed using the Robust Multiar-
ray Analysis algorithm [20]. Up- and downregulated genes were se-
lected based on P values of <0.05 as assessed by two-way ANOVA
using Partek Pro software (Partek, St. Charles, MO, USA). To deter-
mine whether speciﬁc pathways were up- or downregulated, gene on-
tology annotations (www.geneontology.org) were obtained for all
genes represented on the chip. Since the probability that a gene de-
tected is up- or downregulated by chance within a category is 0.5 inFig. 1. Annexin V binding in cells expressing diﬀerent numbers of CGG
between the indicated samples are statistically signiﬁcant.each respective direction, genes signiﬁcantly changed (P < 0.05) in
either direction were ﬁrst counted within each GO category, and sub-
tracted from the number of genes changed in the opposite direction.
The net diﬀerence was expressed as a percentage of the total number
of category members measured. For validation of the microarray data
the Aﬀymetrix target sequence for each gene of interest was masked
using Repeat Masker (http://www.repeatmasker.org/). The primers
(available on request) were designed from this sequence using Applied
Biosystems (Foster City, CA, USA) Primer Express design software
and tested using an in silico PCR tool at UCSC Genome Bioinformat-
ics website. 18s rRNA was used as an endogenous control in real time
PCRs. Fold change was calculated by the delta Ct method [21]. Statis-
tical signiﬁcances for the calculated fold changes were set with an alpha
value of 0.05. An f-test for equal variances was performed to determine
the correct t-test to run and the P-values then calculated.3. Results
The cell lines we used in this study originate from HEK293
cells, which are derived from human embryonic kidney. Since
these cells express many neuron-speciﬁc mRNAs, it is thought
that they may be kidney neural stem cell derivatives [22]. SinceÆ CCG-repeats. The P-values indicate the probability that diﬀerences
Fig. 2. The eﬀect of staurosporine on the survival of CGG-repeat containing cells grown with and without dox. The P-values indicate the probability
that diﬀerences between the indicated samples are statistically signiﬁcant.
Fig. 3. The eﬀect of MG-132 on the survival of cells expressing
CGG Æ CCG-repeats. The P-values indicate the probability that
diﬀerences between the indicated samples are statistically signiﬁcant.
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and there is a large body of work on other repeat expansion
diseases with similar neuronal pathology using this cell line,
we decided to use it in our initial studies.
The cell lines we generated, FRT0, FRT22, FRT30, FRT120
and FRT176, are isogenic except for the number of
CGG Æ CCG-repeats (0, 22, 30, 120 and 176, respectively) be-
tween a dox-inducible promoter and a luciferase open reading
frame. CGG-RNA levels were veriﬁed by real-time PCR using
luciferase-speciﬁc probes and primers. All cell lines expressed
the CGG-RNA even in the absence of dox (data not shown).
However, real-time PCR showed that in the presence of dox
FRT176 makes 2–3 times more CGG-RNA than in the ab-
sence of dox. This corresponds to 8.5 (±2.5) times more
RNA than endogenous FMR1 mRNA. However, FMR1
mRNA levels in premutation carriers can be as much as 10
times that seen than unaﬀected individuals [14]. Thus the level
of CGG-RNA synthesized in FRT176 is likely to be quite sim-
ilar to that of the endogenous FMR1 mRNA in Fragile X pre-
mutation carriers.
When these cell lines were grown with dox, a repeat-length
related increase in the number of Annexin V-positive cells
was observed (Fig. 1). Annexin V binds phosphatidyl serine
(PS) located in the plasma membrane. PS is only accessible
to Annexin V during apoptosis when the PS moves from the
inner to the outer plasma membrane, or during necrosis when
membrane integrity is lost. While the absolute level of cell
death was relatively modest, in FRT176 the number of dying
cells was statistically signiﬁcant amounting to 6 times that
seen in the cell line with 0 repeats. Other repeat-containing cell
lines showed lower levels of cell death that were nonetheless
above that seen in the 0 repeat cell line. While the diﬀerences
for these cell lines were not all statistically signiﬁcant, the trend
is consistent with the idea that the cell death is related to repeat
number. Cell death was reduced in absence of dox suggesting
that it is related to the amount of the CGG-RNA synthesized.
The amount of cell death in FRT176 is similar to that seen inneuronally derived cells and mice expressing an integrated full-
length mutant Huntingtin gene [23]. The low level of cell death
is consistent with the fact that the symptoms of HD, FXPOF
and FXTAS take decades to become apparent. FRT176 was
also more sensitive to staurosporine, an external apoptotic
stimulus (Fig. 2). This eﬀect was not seen in the absence of
dox (Fig. 2) suggesting that it too is related to the levels of
CGG-containing transcript.
No evidence of caspase-1, -3, -8 or poly(ADP-ribose) poly-
merase-1 activation was detected in the repeat-containing cell
lines (data not shown). It may be either that the amount of
Fig. 4. The eﬀect of serum deprivation on cells expressing CGG Æ CCG-repeats.
Fig. 5. The eﬀect of paraquat on cells expressing CGG Æ CCG-repeats.
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our assays or that the cell death we observe is independent
of these proteins. This ﬁnding seems to diﬀer from models of
polyglutamine-mediated toxicity involving truncated versions
of the mutant protein. However, in humans, mice, Drosophila,
and HEK293 cells expressing the full length mutant protein lit-
tle or no evidence for apoptosis is seen either [24–26].
Ubiquitin-positive inclusions in the brains of individuals
with FXTAS [10] suggest a problem with protein folding. If
the cell death we observe is related to protein misfolding,
FRT176 might be more sensitive to agents that interfere with
the cells ability to degrade such proteins. A small increased
sensitivity of FRT176 to 3 lM MG-132, an inhibitor of the
proteasome was seen (Fig. 3), however no signiﬁcant eﬀect
was seen at concentrations where the toxicity is much lower.
The FRT cells show a repeat-length related sensitivity to ser-
um deprivation. The cells, while still viable, become detached
from the growth surface sooner than cells without repeats, rap-
2706 V. Handa et al. / FEBS Letters 579 (2005) 2702–2708idly forming large aggregations of rounded cells (Fig. 4). This
is probably not due to oxidative damage since no sensitivity to
paraquat, a source of free radicals, was seen (Fig. 5). The sen-
sitivity to detachment may have relevance for the symptoms
seen in premutation carriers since some cells are prone to
detachment-induced apoptosis (anoikis). The eﬀect of serum
deprivation was independent of dox, suggesting either that
detachment was not caused by the CGG-RNA or that the ef-
fect of the RNA was saturated at relatively low levels.
Microarray analysis of FRT176 and FRT0 showed a
number of processes impacted by the expression of the CGG-
RNA (Table 1). On an individual level it was possible to iden-
tify a number of genes that could play some role in sensitizing
FRT176 to apoptotic stimuli (Table 2). Most gene expression
changes detected by microarray were modest (<3-fold). Five
genes upregulated in the microarray analysis were chosen forTable 1
Altered biological processes
GO function Score
Upregulated processes
S-Adenosylmethionine-dependent methyltransferase activity 33.3
tRNA aminoacylation for protein translation 18.8
Amino acid transport 17.4
Chaperone activity 12.5
Glucose catabolism 11.5
Ubiquitin cycle 11.1
Protein folding 10.7
Isomerase activity 10.6
Downregulated processes
Oxygen binding 35.7
Cytosolic calcium ion concentration elevation 33.3
Nuclear pore 29.4
Transcriptional activator activity 18.5
Glycoprotein biosynthesis 17.1
Lipid catabolism 16.7
Growth 15.0
Transcription initiation 14.8
Intermediate ﬁlament 14.3
Epidermal diﬀerentiation 13.3
Anti-apoptosis 12.5
Cell cycle arrest 12.5
Symporter activity 11.9
Chemotaxis 10.5
Table 2
Apoptosis related genes demonstrating signiﬁcant changes in gene expressio
Gene Description
Downregulated anti-apoptosis genes
AZU1 Azurocidin 1 (cationic antimicrobial protei
DAD1 Defender against cell death 1
HDAC1 Histone deacetylase 1
MYBL2 v-myb myeloblas tosis viral oncogene hom
NOTCH2 Notch homolog 2 (Drosophila)
TNFRSF6 Tumor necrosis factor receptor super fami
TNFRSF7 Tumor necrosis factor receptor super fami
Upregulated apoptosis genes
APP Amyloid beta (A4) precursor pro tein (pro
CASP8 Caspase-8, apoptosis-related cysteine prote
CTNNAL1 Catenin (cadherin-associated protein), alph
DATF1 Death-associated transcription factor 1
PRSS25 Protease, serine, 25
TIA1 TIA1 Cytotoxic granule-associated RNA b
TIAF1 TGFB1-induced anti-apoptotic factor 1validation by RT-PCR (Table 3). Of these four genes, CY-
FIP1, caspase-8, neurotensin and UBE3A were found to have
signiﬁcantly increased expression with P values <0.05.4. Discussion
In an eﬀort to understand the eﬀect of long CGG Æ CCG-re-
peat tracts on gene expression and cell survival we have devel-
oped a number of otherwise isogenic human cell lines
expressing transcripts with diﬀerent numbers of CGG-repeats.
The repeat number in these cell lines was stable in all but the
cell line derived from the plasmid with the largest number of
repeats (pFRT176). A similar variation in repeat number
was seen in a number of independently derived clones and is
consistent with the known instability of longer repeat tracts.
The FRT176 cell line, which produces physiologically reason-
able amounts of RNA with CGG-repeat numbers in the pre-
mutation range, shows an altered gene expression proﬁle.
Expression of this RNA also causes an increase in the likeli-
hood of cell death. These cells are also sensitive to serum-
deprivation-induced detachment which can induce apoptosis
in some cells.
Microarray analysis suggests that long CGG-containing
RNAs aﬀect a variety of biological processes. Downregulated
processes include oxygen binding and Ca2+ concentration ele-
vation which could negatively aﬀect neuronal health and syn-
aptic function, respectively. Upregulated processes include
increasing chaperone activity and ubiquitination both of which
would be consistent with a protein misfolding problem. One of
the ubiquitin-related genes upregulated in FRT176 is UBE3A,
which encodes the E6-AP ubiquitin E3 ligase. Increased
expression of this gene is interesting given that elevated levels
of this gene product may be associated with autism [27], since
autistic-like symptoms are seen in some Fragile X premutation
carriers [28]. Transcription of caspase-8, which is part of the
death receptor-induced apoptotic pathway, is also upregu-
lated. While we saw no evidence under normal growth condi-
tions of increased caspase-8 activation, elevated levels of
caspase-8 may sensitize premutation carriers to the eﬀects of
apoptotic stimuli. Interestingly, Parkin, an anti-apoptotic pro-
tein, is a caspase-8 substrate [29]. Parkin cleavage is thought ton
Probe set
n 37) 214575_s_at
200046_at
201209_at
olog (avian)-like 201710_at
212377_s_at
ly, member 6 204781_s_at
ly, member 7 206150_at
tease nexin-II, Alzheimer disease) 200602_at
ase 213373_s_at
a-like 1 202468_s_at
213213_at
203089_s_at
inding protein 201450_s_at
202039_at
Table 3
Real-time PCR validation of genechip results
Gene name Probe set Genechip fold change P-value RT-PCR fold change P-value
APP 214953_s_at 1.86 0.0183 1.95 0.0573
CASP8 213373_s_at 2.42 0.00101 2.86 8.68E07
CYFIP1 208923_at 1.90 0.0000257 2.64 2.15E05
NTS 206291_at 3.19 0.00414 13.90 1.07E09
UBE3A 211285_s_at 2.43 0.000309 2.34 0.00552
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seen in individuals with FXTAS [30]. Cytoplasmic FMRP-
interacting protein 1 (CYFIP1) controls neuronal connectivity
via binding to the rho-GTPase rac1 and FMRP [31]. Excess
CYFIP1 might aﬀect the balance necessary for optimal synap-
tic function that is mediated by these proteins. Neurotensin
(NT), a tridecapeptide found predominantly in the brain and
gut, is involved in motor coordination, balance, and gut motil-
ity. NT is also an important component of the hypothalamic–
pituitary–gonadal axis important for regulating female fertility
[32].
Work is now in progress to examine the relationship between
the altered expression of these genes and the symptoms seen in
carriers of FXS premutation alleles.References
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